|
Most efficient bacteria test-world record set
by Mobidiag
[April
23] HELSINKI, Finland--The Finnish biotechnology company Mobidiag
announced today the Prove-it™ Bacteria test sets a world record
for the Most
efficient batcteria test by being able to detect 50
dangerous bacteria simultaneously - including the widespread
“superbug” MRSA.
This is an important milestone in the battle against
infectious diseases, most importantly life-threatening sepsis.
(enlarge
photo)
Sepsis is a growing cause of death worldwide -
there are around 3 million sepsis cases annually, over 500,000
of them resulting in death. Sepsis is an infection caused
by a number of micro-organisms spreading in the bloodstream.
The challenge in sepsis treatment is starting adequate treatment
with the appropriate antibiotics on time.
Currently, the diagnostics of causative
pathogen(s) needed for the antibiotic treatment decision takes
2-5 days based on blood culturing and subsequent pathogen
identification.
Using
Mobidiag’s Prove-it™ Bacteria, the pathogen detection is available
1-3 days earlier compared to current diagnostics. The PCR
and microarray-based test takes less than three hours to complete.
Achieved time saving rationalizes antibiotic
treatment and improves patient outcomes and decreases mortality
considerably.
Jaakko Pellosniemi, CEO of Mobidiag:
“Our Prove-it™ Bacteria test has all the potential to revolutionize
microbial sepsis diagnostics. The test helps clinicians make
better and faster decisions and provide sufficient treatment
for seriously ill patients. This offers huge savings, as sepsis
treatment currently consumes billions of euros annually. Our
target is to have a single test that reliably detects the
majority of dangerous human disease causing bacteria and Prove-it™
Bacteria test is an important milestone on that road,”
“I strongly believe that Prove-it™ products will
rapidly gain foothold on the multibillion microbial diagnostic
markets” said Pellosniemi.
Prove-it™ Bacteria test is initially intended
for research purposes. The evaluation aiming for the European
CE-IVD status enabling its use in clinical sepsis diagnostics
is currently ongoing and will be completed later this year.
The test will cover more than 90 % of all sepsis cases.
Founded in 2001, Mobidiag
develops rapid diagnostic tests for hospital laboratories.
The Prove-it™ Bacteria test is developed in co-operation with
Hospital Districts of Helsinki and Uusimaa, Finland.
|
